

# ViroSpot microneutralization assay for antigenic characterization of human influenza viruses

Carel A. van Baalen<sup>a,\*</sup>, Rienk E. Jeeninga<sup>a</sup>, Germaine H.W.M. Penders<sup>a</sup>, Brenda van Gent<sup>a</sup>, Ruud van Beek<sup>b,c</sup>, Marion P.G. Koopmans<sup>b,c</sup>, Guus F. Rimmelzwaan<sup>b,c</sup> <sup>a</sup> Viroclinics Biosciences B.V., Rotterdam, The Netherlands; <sup>b</sup> Department of Viroscience, Erasmus Medical Center, Rotterdam, The Netherlands <sup>c</sup> WHO National Influenza Center (NIC), Rotterdam, The Netherlands

**E-mail address:**

**[baalen@viroclinics.com](mailto:baalen@viroclinics.com) (C.A. van Baalen)**

*\*Corresponding author at : Viroclinics Biosciences B.V.  
Marconistraat 16 3029 AK Rotterdam The Netherlands.*





# ViroSpot microneutralization assay for antigenic characterization of human influenza viruses

Learn more about Viroclinics-DDL contributions to vaccine  
and antiviral development :

[www.cerbaresearch.com](http://www.cerbaresearch.com)

[cerbaresearch.com](http://cerbaresearch.com)  
Cerba Research Netherlands

<https://cerbaresearch.com/contact-us/>

Marconistraat 16, 3029 AK Rotterdam, The Netherlands

